GlaxoSmithKline
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
GSK1349572 Proton Pump Inhibitor Drug Interaction and Supratherapeutic Dose Study
- Conditions
- Healthy Volunteer
- Interventions
- First Posted Date
- 2009-07-20
- Last Posted Date
- 2009-10-09
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 24
- Registration Number
- NCT00942136
- Locations
- 🇺🇸
GSK Investigational Site, Baltimore, Maryland, United States
A Study to Test the Benefit of a New Anti-cancer Treatment in Patients With Unresectable Advanced Melanoma
- Conditions
- Melanoma
- Interventions
- Biological: Immunotherapeutic GSK2132231A
- First Posted Date
- 2009-07-20
- Last Posted Date
- 2020-12-08
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 125
- Registration Number
- NCT00942162
- Locations
- 🇪🇸
GSK Investigational Site, Madrid, Spain
Single Dose Study of Controlled-Release Paroxetine Tablets in Healthy Japanese Male Subjects
- Conditions
- Depressive Disorder
- Interventions
- First Posted Date
- 2009-07-13
- Last Posted Date
- 2018-06-19
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 18
- Registration Number
- NCT00938184
- Locations
- 🇯🇵
GSK Investigational Site, Tokyo, Japan
A Study of the Pharmacokinetics of Albiglutide in Normal and Renally Impaired Subjects.
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Biological: albiglutide
- First Posted Date
- 2009-07-13
- Last Posted Date
- 2017-07-21
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 75
- Registration Number
- NCT00938158
- Locations
- 🇿🇦
GSK Investigational Site, Somerset West, South Africa
Reactogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Rotarix™ (Human Rotavirus Vaccine) in Indian Infants
- Conditions
- Infections, Rotavirus
- Interventions
- Biological: Rotarix™
- First Posted Date
- 2009-07-13
- Last Posted Date
- 2018-01-02
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 332
- Registration Number
- NCT00938327
- Locations
- 🇮🇳
GSK Investigational Site, Pune, India
Retreatment of Patients With Non-Hodgkin's Lymphoma Who Have Previously Responded to Iodine-131 Anti B1 Antibody
- Conditions
- Lymphoma, Non-Hodgkin
- Interventions
- Biological: Tositumomab and Iodine I 131 Tositumomab
- First Posted Date
- 2009-07-13
- Last Posted Date
- 2017-01-09
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 32
- Registration Number
- NCT00938041
Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza Vaccine for the Elderly
- Conditions
- Influenza
- Interventions
- Biological: GSK investigational FluNG vaccine GSK2186877A, aged lotBiological: GSK investigational FluNG vaccine GSK2186877A, fresh lot
- First Posted Date
- 2009-07-13
- Last Posted Date
- 2018-08-20
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 726
- Registration Number
- NCT00938392
- Locations
- 🇸🇰
GSK Investigational Site, Velky Biel, Slovakia
Safety and Reactogenicity of GSK Biologicals' Inactivated Poliomyelitis Vaccine (IPV) (Poliorix) in Infants
- Conditions
- Poliomyelitis
- Interventions
- Biological: Poliorix
- First Posted Date
- 2009-07-13
- Last Posted Date
- 2018-12-17
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 25
- Registration Number
- NCT00937404
- Locations
- 🇨🇳
GSK Investigational Site, Wuzhou, Guangxi, China
Brain Uptake of GSK1034702: a Positron Emission Tomography (PET) Scan Study
- First Posted Date
- 2009-07-13
- Last Posted Date
- 2017-06-27
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 4
- Registration Number
- NCT00937846
- Locations
- 🇬🇧
GSK Investigational Site, London, United Kingdom
Gynaecological Follow-up of a Subset of 580299/008 (NCT00122681) Study Subjects
- Conditions
- Infections, Papillomavirus
- Interventions
- Other: Gynaecological follow-up
- First Posted Date
- 2009-07-13
- Last Posted Date
- 2019-10-29
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 2022
- Registration Number
- NCT00937950
- Locations
- 🇬🇧
GSK Investigational Site, Manchester, United Kingdom